Prot #NKT2152-101: A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of NKT2152, an Orally Administered HIF-2α Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal

Project: Research project

Project Details

StatusActive
Effective start/end date5/23/25 → 5/23/28

Funding

  • Medpace Clinical Research LLC (Prot #NKT2152-101 // Prot #NKT2152-101)
  • NiKang Therapeutics, Inc. (Prot #NKT2152-101 // Prot #NKT2152-101)